Business Standard

Pfizer vaccine's -70 degree storage norm tough for most nations: V K Paul

Limited number of doses would not be enough to meet India's demand, adds Niti Aayog member

Pfizer
Premium

US drug-maker Pfizer has reported that its vaccine BNT162b2, has been more than 90 per cent effective in late-stage trials.

Ruchika Chitravanshi New Delhi
As the national committee on covid vaccine firms up the national scheme for vaccine distribution and evaluates the available vaccine options, the government feels that not only do the cold chain requirements for Pfizer’s candidate pose a major challenge, its limited number of doses would not be enough to meet India’s demand. 

“In our knowledge there is only one vaccine that needs to be kept in -70 to -80 degree Celsius temperature which will be difficult for all countries which make it difficult to scale up...We are discussing this as the Pfizer’s vaccine will not be available to us for

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in